Q1 2025 Earnings Summary
Metric | YoY Change | Reason |
---|---|---|
Total Revenue | Down 18% (from $225,131 to $184,473) | Revenue decreased by $40,658, largely due to intensified competition in the cannabis telemedicine industry that has been negatively impacting demand, a trend observed in previous periods as well. |
Net Loss | Improved by nearly 52% (from $222,568 to $107,364) | Net loss narrowed significantly, reflecting successful cost control measures that helped reduce operating and non-operating expenses compared to the previous period, contributing to overall improved profitability performance despite a lower revenue base. |
Operating Expenses | Down 27% (from $300,904 to $218,581) | Operating expenses were trimmed by $82,323, building on earlier cost-cutting initiatives; reductions in wages, salaries, and other overheads have helped lower overall expenses in Q1 2025 relative to Q1 2024. |
Wages & Salaries | Down from $114,071 to $73,390 | Employee costs decreased by approximately $40,681, demonstrating continued aggressive cost management in personnel expenses, a measure already emphasized in earlier periods. |
Cash Flow | Turned from –$24,744 to +$4,129 | A positive shift in operating cash flow by nearly $28,873 was achieved due to tighter cash management and improved efficiency in operations, marking a reversal of the negative trend observed in Q1 2024. |
Gross Margin | Improved from 56% to 63% | Gross margin increased despite a drop in absolute gross profit (from $126,113 to $116,967) because cost of sales declined more than revenue, reflecting enhanced cost leverage and pricing strategies implemented over prior periods. |
Research analysts covering CBDS.